DASH vs SPRO · P/E 76, rev $13.72B vs P/E 9.6, rev $48.0M
DoorDash, Inc. Class A Common Stock (DASH) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the DASH and SPRO stock pages for the full models.
Not investment advice.